Daily administration ofm-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Psychopharmacology

• Publication date

  1996-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/BF02805987PMID 8888380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison

  2018cited by this paper
• Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin

  2005cited by this paper
• Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity

  2005cited by this paper
• Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion

  2005cited by this paper
• Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)

  2005cited by this paper
• Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations

  2005cited by this paper
• Effects of housing, restraint and chronic treatments withmCPP and sertraline on behavioural responses tomCPP

  2005cited by this paper
• Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers

  2004cited by this paper
• 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerts an anorexic action that is blocked by 5-HT2 antagonists in rats

  2004cited by this paper
• Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans

  2004cited by this paper
• Evidence thatm-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2C receptors

  1996cited by this paper
• Psychopharmacology: The Fourth Generation of Progress

  1995cited by this paper
• Lack of Cross-Tolerance for Hypophagia Induced by DOI versus m-CPP Suggests Separate Mediation by 5-HT2A and 5-HT2C Receptors, Respectively

  1995cited by this paper
• Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment.

  1995cited by this paper
• Serotonin and Thermoregulation

  1995cited by this paper
• Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: a preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures.

  1995cited by this paper
• Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors

  1995cited by this paper
• Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans

  1995cited by this paper
• Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function.

  1994cited by this paper
• Evidence that 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane-induced hypophagia and hyperthermia in rats is mediated by serotonin-2A receptors.

  1994cited by this paper
• Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP).

  1994cited by this paper
• Fluoxetine Alters the Effects of Intravenous Cocaine in Humans

  1994cited by this paper
• In vivo properties of SB 200646A, a 5‐HT2C/2B receptor antagonist

  1994cited by this paper
• Behavioral responses to intravenous meta-chlorophenylpiperazine in patients with seasonal affective disorder and control subjects before and after phototherapy.

  1994cited by this paper
• International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

  1994cited by this paper
• Role of various 5-HT receptor subtypes in mediating neuroendocrine effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats.

  1994cited by this paper
• Attenuation of the Prolactin‐Stimulating and Hyperthermic Effects of Nefazodone After Subacute Treatment

  1994cited by this paper
• Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.

  1993cited by this paper
• Novel regulation of 5-HT1C receptors: down-regulation induced both by 5-HT1C/2 receptor agonists and antagonists.

  1993cited by this paper
• Tolerance and sensitization to the behavioral effects of drugs.

  1993cited by this paper
• Calcineurin inhibits desensitization of cloned rat 5-HT1C receptors

  1993cited by this paper
• Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.

  1993cited by this paper
• Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats.

  1993cited by this paper
• The effects of 5-HT and m-chlorophenylpiperazine (m-CPP) on the efflux of [3H]-5-HT from human perfused platelets.

  1993cited by this paper
• Altered prolactin response to clomipramine rechallenge in healthy subjects.

  1993cited by this paper
• Effect of selective serotonin agonists on basal, corticotrophin-releasing hormone- and vasopressin-induced ACTH release in vitro from rat pituitary cells.

  1993cited by this paper
• A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.

  1993cited by this paper
• Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats.

  1992cited by this paper
• Test-retest reliability of the prolactin and cortisol responses to D,L-fenfluramine challenge in disruptive behavior disorders.

  1992cited by this paper
• mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors.

  1992cited by this paper
• Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects.

  1992cited by this paper
• Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects.

  1991cited by this paper
• Long-term administration of m-chlorophenylpiperazine to rats does not alter functional sensitivity of either pre-synaptic or postsynaptic 5-HT1A receptors

  1991cited by this paper
• Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects.

  1991cited by this paper
• A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease.

  1991cited by this paper
• Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.

  1991cited by this paper
• The Biological bases of drug tolerance and dependence

  1991cited by this paper
• m-Chlorophenylpiperazine as a probe of serotonin function.

  1991cited by this paper
• Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans.

  1991cited by this paper
• Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.

  1991cited by this paper
• The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP

  1991cited by this paper
• Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects.

  1990cited by this paper
• Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients. Initial experience with a serotonin agonist.

  1990cited by this paper
• Serotonin1c receptor reserve in choroid plexus masks receptor subsensitivity.

  1990cited by this paper
• Behavioural evidence for functional interactions between 5‐HT‐receptor subtypes in rats and mice

  1990cited by this paper
• Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study.

  1990cited by this paper
• Nefazodone: preclinical pharmacology of a new antidepressant.

  1990cited by this paper
• Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes.

  1989cited by this paper
• Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists.

  1989cited by this paper
• Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study.

  1989cited by this paper
• Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects.

  1989cited by this paper
• Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?

  1989cited by this paper
• 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain.

  1989cited by this paper
• Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.

  1988cited by this paper
• Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.

  1987cited by this paper
• Serotonin function in anxiety

  1987cited by this paper
• Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors.

  1987cited by this paper
• Diminished prolactin responses to repeated fenfluramine challenge in man.

  1987cited by this paper
• Norepinephrine challenges in panic patients.

  1986cited by this paper
• Norepinephrine challenges in panic patients.

  1986cited by this paper
• CO2 inhalation in the treatment of panic attacks.

  1986cited by this paper
• Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies.

  1986cited by this paper
• Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP.

  1985cited by this paper
• Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.

  1985cited by this paper
• 1‐m‐Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole

  1982cited by this paper
• Uptake of [3H]5‐hydroxytryptamine and [3H]noradrenaline by slices of rat brain incubated in plasma from patients treated with chlorimipramine, imipramine or amitriptyline

  1973cited by this paper
• The role of norfenfluramine in fenfluramine‐induced mydriasis

  1973cited by this paper
• Lactate Infusion in the Treatment of ‘Free-Floating’ Anxiety *

  1973cited by this paper

• Metabolism of m-CPP, trazodone, nefazodone, and etoperidone: clinical and forensic aspects

  2025cites this paper
• Obstructive Sleep Apnea and Serotoninergic Signalling Pathway: Pathomechanism and Therapeutic Potential

  2024cites this paper
• Evaluating pharmacological models of high and low anxiety in sheep

  2015cites this paper
• Controversies on the role of 5-HT(2C) receptors in the mechanisms of action of antidepressant drugs.

  2014cites this paper
• Qualitative Research of Online Drug Misuse Communities with Reference to the Novel Psychoactive Substances

  2013cites this paper
• Trazodone: properties and utility in multiple disorders

  2011cites this paper
• The Role of 5-HT2C Receptors in the Antidepressant Response: A Critical Review

  2010cites this paper
• 5-HT2C ligands: recent progress.

  2008cites this paper
• Single-blind and Double-blind Randomized Controlled Trials of Palmtherapy®, an Alternative Medical Approach, for Anxiety before Cardiac Catheterization

  2007cites this paper
• Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs

  2007cites this paper
• N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed.

  2007cites this paper
• [Metachlorophenylpiperazine (mCPP): a new designer drug].

  2006cites this paper
• La métachlorophénylpipérazine (mCPP) : une nouvelle drogue de synthèse

  2006cites this paper
• Anxiogenic treatments do not increase fear-potentiated startle in mice.

  2005cites this paper
• Metabolism of designer drugs of abuse.

  2005cites this paper
• Effects on pain and anxiety of patients viewing their cystoscopy in addition to a detailed explanation: a controlled study

  2003cites this paper
• Serotonin Agonists and Antagonists in Obstructive Sleep Apnea

  2003cites this paper
• Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone.

  2003cites this paper
• 5-HT2C receptor mediation of unconditioned escape behaviour in the unstable elevated exposed plus maze

  2002cites this paper
• Ethopharmacological analysis of the unstable elevated exposed plus maze, a novel model of extreme anxiety: predictive validity and sensitivity to anxiogenic agents

  2002cites this paper
• Challenge paradigms in psychiatric research: what do they contribute and are they ethical?

  2002cites this paper
• Influence of the serotonin antagonist, metergoline, on the anxiogenic effects of carbon dioxide, and on heart rate and neuroendocrine measures, in healthy volunteers

  2001cites this paper
• Episodic encephalopathy with dilated pupils

  2001cites this paper
• Lack of association between joint hyperlaxity and, I: panic disorder, and II: reactivity to carbon dioxide in healthy volunteers

  2001cites this paper
• Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of meta-chlorophenylpiperazine in normal volunteers.

  2001cites this paper
• Attenuated response to m-CPP and to pentagastrin after repeated m-CPP in panic disorder

  1999cites this paper
• Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats.

  1998cites this paper
• Metabolism of the Newer Antidepressants

  1998cites this paper
• Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan.

  1998cites this paper
• Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.

  1998cites this paper
• Brain‐to‐blood partition and in vivo inhibition of 5‐hydroxytryptamine reuptake and quipazine‐mediated behaviour of nefazodone and its main active metabolites in rodents

  1998cites this paper
• The role of 5-HT2C receptors in affective disorders.

  1998cites this paper
• Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients

  1998cites this paper
• Plasma levels of m-chlorophenylpiperazine following single oral dose administration of m-chlorophenylpiperazine and trazodone in human volunteers.

  1997cites this paper
• Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment

  1997cites this paper
• Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder.

  1997cites this paper
• Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.

  1997cites this paper
• SSRI treatment decreases prolactin and hyperthermic responses to mCPP

  1997cites this paper
• Biological concepts of anxiety disorders

  1997cites this paper
• 5-HT2C receptor activation decreases appetite and body weight in obese subjects

  1997cites this paper